5 Key Takeaways

• 1

  Ophthalmology practices must navigate fraud and abuse risks alongside FDA regulations when adopting AI clinical decision support tools.

• 2

  The Practice Fusion case highlights the importance of vendor transparency and independence in AI tool development to mitigate compliance risks.

• 3

  AI-generated documentation must be reviewed by clinicians to prevent inaccuracies that could lead to False Claims Act liabilities.

• 4

  Ophthalmology reimbursement relies on accurate documentation of medical necessity, necessitating careful use of AI-generated justification language.

• 5

  The FDA has updated its guidance to expand the scope of non-device clinical decision support tools, promoting innovation in AI applications.